

## **Dianthus Therapeutics Expanded Access Policy**

Dianthus is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Our goal is to provide access to our investigational therapies at the appropriate time and in the correct manner for patients.

Currently, we do not provide expanded access to our investigational products and do not accept expanded access requests. Expanded access, sometimes referred to as compassionate use, refers to the use of an investigational therapy outside a clinical trial when the primary purpose is to diagnose, prevent, or treat a serious condition or immediately life-threatening disease or condition in patients who lack satisfactory therapeutic alternatives. This is different from a clinical trial, where more comprehensive safety and efficacy data are collected. We understand the need for expanded access programs, and we recognize the importance of having an appropriate policy.

We are committed to developing safe and effective therapies, obtaining regulatory approval, and providing our therapies as quickly as possible to patients who are most likely to benefit. At this time, we believe that participation in one of our clinical trials is the appropriate way to access our investigational therapies. We encourage all individuals who think they may benefit from Dianthus investigational products to speak to their physicians about the possibility of enrolling in a clinical trial to support the development of promising new products. Treating physicians, patients, and/or caregivers can learn more about our investigational products in ongoing clinical trials, including study contacts to obtain more specific information, by visiting [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and searching for “Dianthus Therapeutics, Inc.” in the Other Terms search field.

If you have additional questions, please speak with your physician or contact [EAP@dianthustx.com](mailto:EAP@dianthustx.com). We anticipate acknowledging receipt of requests sent to this email within five business days. Please do not send any personal or private health information to this email address.

Dianthus may revise this policy at any time. This website and policy will be updated with a hyperlink or other reference to the expanded access record on [ClinicalTrials.gov](http://ClinicalTrials.gov) after such record becomes active.